FIGURE 1A Abbott Architect i2000 (I) Abbott Architect i2000 (I) Ratio

Slides:

Advertisements

Similar presentations

BioConsulting Solutions Bridging Commercialization and Science BioConsulting Solutions BRIDGING COMMERCIALIZATION AND SCIENCE August 2005 (Medical) Device.

Advertisements

Between-Method Differences in Prostate Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms C. Stephan, K. Siemβen, H. Cammann,

Supplemental Data Fig. 1. Results from commutability study for hGH. Plotted are the measurement results for clinical samples, hGH preparations, and control.

The Importance of Commutability of Reference Materials Used as Calibrators: The Example of Ceruloplasmin I. Zegers, R. Beetham, T. Keller, J. Sheldon,

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Clinical Chemistry Gregory S. Travlos, DVM, DACVP National Institute of Environmental Health Sciences Research Triangle Park, NC

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

1 Thyroid Testing Strategies in the South-West and Wessex A survey conducted on behalf of the ACB SW&W Regional Committee by Roberta Goodall.

Measurements for 8 Common Analytes in Native Sera Identify Inadequate Standardization among 6 Routine Laboratory Assays H.C.M. Stepman, U. Tiikkainen,

Evaluation of Beckton-Dickinson PST II and SST II Blood Collection Tubes P Graham, B Martin, M Roser, G Jones Department of Chemical Pathology, St Vincent’s.

Establishment of the 1st WHO International Standard for Detection of Antibodies to Hepatitis B Virus Core Antigen (anti-HBc) SoGAT XXI 29 May 2009 Dr.

Accuracy of 6 Routine 25-Hydroxyvitamin D assays; Influence of Vitamin D Binding Protein Concentration A.C. Heijboer, M.A. Blankenstein, I.P. Kema, and.

Национальная процедура одобрения и регистрации проектов (программ) международной технической помощи (исключая представление информации об организации и.

© Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Select Cardiac Risk Test Market End User Education Creates Growth Opportunities “With efficient.

Epithelial Tissue 1. ID#1 -- ID this type of epithelium. 2.

Global Biomarkers Industry 2016 Market Research Report

United States Immunodiagnostic Industry Analysis and Revenue Forecast 2016

Which troponin assay to choose? Clinical performances of troponin T and troponin I assays Per Venge, MD PhD Professor Department of Medical Sciences Uppsala.

Introduction The composition of plasma and Cerebrospinal fluid (CSF) are similar with the only major difference between the two being the greatly reduced.

M/z, amu Intensity, cps Figure S1.

基督再來（一）. 經文： 1 你們心裡不要憂愁；你們信神，也當信我。 2 在我父的家裡有許多住處；若是沒有，我就早已告訴你們了。我去原是為你們預備地去。 3 我若去為你們預備了地方，就必再來接你們到我那裡去，我在那裡，叫你們也在那裡， ] ( 約 14 ： 1-3)

Method comparisons - what do we learn from the Nordic Reference Interval Project 2000 (NORIP) Pål Rustad Fürst Medical Laboratory Labquality Days 12/

MarketsandMarkets Presents Blood Screening Market worth $2.5 Billion by html.

Global D-dimer Market 2016 Development Trends and Forecasts Analysis Published: Oct 2016 Single User License: US$ 2900 Corporate User License: US$ 5800.

© 2016 Global Market Insights, Inc. USA. U.S. Autoimmune Diagnostics Market worth USD 3.5 billion by 2023

Global Fully Automated Hematology Analyzers Market Research Report 2017.

In-Vitro Diagnostics Market Driving factors and forecast report

POINT-OF-CARE DIAGNOSTICS MARKET GLOBAL BRIEFING 2017 INCLUDING: GLUCOSE AND CARDIOMETABOLIC MONITORING KITS, INFECTIOUS DISEASES TESTING KITS, CARDIAC.

IMMUNOCHEMISTRY MARKET GLOBAL BRIEFING 2017 INCLUDING: ENZYME-LINKED IMMUNOSORBENT ASSAY, FLUORESCENCE IMMUNOASSAY, CHEMILUMINESCENCE IMMUNOASSAY, COLORIMETRIC.

Harmonization of Serum Thyroid-Stimulating Hormone Measurements Paves the Way for the Adoption of a More Uniform Reference Interval L.M. Thienpont, K.

Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht.

Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides A. K. Saenger, O. Rodriguez-Fraga,

PSEUDO-HYPERTHYROXINAEMIA

Fig. 2. Distribution of vitamin D levels of all samples by Siemens, Abbott, and DiaSorin. The mean (SD) of Siemens, Abbott, and DiaSorin assays was

Inter-laboratory comparison of beta-2 microglobulin methods: impact of assay variation on multiple myeloma staging Pasquale Fedele, Kay-Weng Choy, James.

Fig. 2. Bland-Altman plots of albumin concentrations from Albumin in Urine/CSF FS (DiASys) testing on a BioMajesty JCA-BM6010/C analyzer. (A) Comparison.

© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.

Choosing the Best Urine Benzo Screen for Monitoring Adherence to Alprazolam or Clonazepam Maggie L Hopkins MD MBA1, Elisabeth Malmberg MS2, Bella Church.

Precision Albumin (mg/L) (Mean ± SD) % CV Intra-assay (n = 10)

A What is the ratio of Area to Width of rectangle A? A W 4 u 20 u2

בטיחות בתעשייה בהיבט חברות הביטוח

Monday, 23 July, 10:15-12:15 Hall 11B, RAI Amsterdam

Precision of progesterone measurements with the use of automated immunoassay analyzers and the impact on clinical decisions for in vitro fertilization

(A) (E) (B) (C) (F) (D) Control HLM MLM Chemical synthesis M2 M2'

Early Diagnosis of Myocardial Infarction Using Absolute and Relative Changes in Cardiac Troponin Concentrations Affan Irfan, MD, Tobias Reichlin, MD,

Supplemental Figure. Passing & Bablok regression graphs for each 25(OH)D assay compared with ID-XLC-MS/MS in each clinical subject group. R is shown in.

Слайд-дәріс Қарағанды мемлекеттік техникалық университеті

Increased Sensitivity of the Roche COBAS AMPLICOR HCV Test, Version 2

.. -"""--..J '. / /I/I =---=-- -, _ --, _ = :;:.

Unreliable immunoassays, patients' safety, and clinical research

W. Greg Miller, Graham R.D. Jones Advances in Chronic Kidney Disease

II //II // \ Others Q.

I1I1 a 1·1,.,.,,I.,,I · I 1··n I J,-·

Disclaimer: I have no conflicts of interest

- I 'I'I. 1. ' ' >, h II ItIt I I 1l1l 1 1I1I I1I1 r. 1 t I It n lli I! 'II'II /"'J ' ' I' I,I I,I I...f..,:1 :.:. ; ! 1, I. - f. I J, I:I: ,,,

-·.-...-· A. -.. ) ,.,.. -.,., · o# --·'1>,.. ·-·-. ·-· ;'/' : ,.,. - ' p ·-·- ·-- 'II"; -.-. t-.. p

Objective - To find the area of squares and rectangles.

Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott

به نام خالق زیبایی.

Binary Search Counting

Engine Part ID Part 1.

Engine Part ID Part 2.

Engine Part ID Part 2.

Accuracy of US Food and Drug Administration–cleared IgE antibody assays in the presence of anti-IgE (omalizumab) Robert G. Hamilton, PhD, DABMLI Journal.

. '. '. I;.,, - - "!' - -·-·,Ii '.....,,......, -,

Share your thoughts on this presentation with #IAS2019

A. Ladang, C. Bertholet, L. Vranken, E. Cavalier

ANALYTICAL CONTROL SYSTEM AS A MEASURE TO ENSURE INFECTIOUS SAFETY OF HUMAN PLASMA FOR FRACTIONATION A.L. Poptsov FSBI “ROSPLASMA” RMSPC of FMBA of RUSSIA.

Presentation transcript:

FIGURE 1A Abbott Architect i2000 (I) Abbott Architect i2000 (I) Ratio 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Ratio 10.0 9.0 8.0 7.0 6.0 Ratio 5.0 4.0 3.0 2.0 1.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Abbott Architect i2000 (II) Abbott Architect i2000 (II) 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Ratio 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Ratio 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Beckman Coulter Access Beckman Coulter Access 10.0 10.0 9.0 9.0 8.0 8.0 7.0 7.0 6.0 6.0 Ratio Ratio 5.0 5.0 4.0 4.0 3.0 3.0 2.0 2.0 1.0 1.0 0.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Siemens Coat a Count DPC Siemens Coat a Count DPC 10.0 10.0 9.0 9.0 8.0 8.0 7.0 7.0 6.0 6.0 Ratio 5.0 Ratio 5.0 4.0 4.0 3.0 3.0 2.0 2.0 1.0 1.0 0.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Siemens ADVIA Centaur Siemens ADVIA Centaur Ratio Ratio 10.0 10.0 9.0 9.0 8.0 8.0 7.0 7.0 6.0 6.0 Ratio 5.0 Ratio 5.0 4.0 4.0 3.0 3.0 2.0 2.0 1.0 1.0 0.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Siemens Immulite 2000 Siemens Immulite 2000 Ratio Ratio 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Ratio 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Ratio 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Roche Cobas (II) Roche Cobas (II) Ratio Ratio ID-LC-MS/MS (nmol/L) 10.0 10.0 9.0 9.0 8.0 8.0 7.0 7.0 6.0 6.0 Ratio Ratio 5.0 5.0 4.0 4.0 3.0 3.0 2.0 2.0 1.0 1.0 0.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

FIGURE 1B Abbott Architect i2000 (I) Abbott Architect i2000 (I) Ratio 2.0 2.0 1.8 1.8 1.6 1.6 1.4 1.4 1.2 1.2 Ratio Ratio 1.0 1.0 0.8 0.8 0.6 0.6 0.4 0.4 0.2 0.2 0.0 0.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Abbott Architect i2000 (II) Abbott Architect i2000 (II) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 Ratio Ratio 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Beckman Coulter Access Beckman Coulter Access 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.0 1.8 1.6 1.4 1.2 Ratio Ratio 1.0 0.8 0.6 0.4 0.2 0.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Siemens Coat a Count DPC Siemens Coat a Count DPC 2.0 2.0 1.8 1.8 1.6 1.6 1.4 1.4 1.2 1.2 Ratio 1.0 Ratio 1.0 0.8 0.8 0.6 0.6 0.4 0.4 0.2 0.2 0.0 0.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Siemens ADVIA Centaur Siemens ADVIA Centaur Ratio Ratio 2.0 2.0 1.8 1.8 1.6 1.6 1.4 1.4 1.2 1.2 Ratio Ratio 1.0 1.0 0.8 0.8 0.6 0.6 0.4 0.4 0.2 0.2 0.0 0.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)

Siemens Immulite 2000 Siemens Immulite 2000 Ratio Ratio 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 Ratio Ratio 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 ID-LC-MS/MS (nmol/L) 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 ID-LC-MS/MS (nmol/L)

Roche Cobas (II) Roche Cobas (II) Ratio Ratio ID-LC-MS/MS (nmol/L) 2.0 2.0 1.8 1.8 1.6 1.6 1.4 1.4 1.2 1.2 Ratio Ratio 1.0 1.0 0.8 0.8 0.6 0.6 0.4 0.4 0.2 0.2 0.0 0.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 4.0 8.0 12.0 16.0 20.0 24.0 28.0 32.0 36.0 40.0 ID-LC-MS/MS (nmol/L) ID-LC-MS/MS (nmol/L)